Literature DB >> 21329405

Delivering for aphasia.

Chris Code1, Brian Petheram.   

Abstract

Providing a quality service for people with aphasia is a primary goal of speech-language pathologists working with neurogenic communication disorders. This paper reviews what is known about the incidence and prevalence of aphasia and what services are provided for people with aphasia. On the basis of the stroke data, the incidence of aphasia in the developed world ranges between 0.02-0.06% with prevalence ranging between 0.1-0.4%. Average hours of treatment for aphasic people in the developed world ranges between 1-5 hours per week, with a great deal of variability, although recent research suggests that intense treatment of ∼9 hours per week over a relatively short period is needed in order to be effective. It is concluded that there is a significant gap between what the research suggests is the appropriate amount of treatment and actual provision throughout the English-speaking world.

Entities:  

Mesh:

Year:  2011        PMID: 21329405     DOI: 10.3109/17549507.2010.520090

Source DB:  PubMed          Journal:  Int J Speech Lang Pathol        ISSN: 1754-9507            Impact factor:   2.484


  13 in total

1.  Thinking About Better Speech: Mental Practice for Stroke-Induced Motor Speech Impairments.

Authors:  Stephen J Page; Stacy Harnish
Journal:  Aphasiology       Date:  2012       Impact factor: 2.773

Review 2.  Piracetam for Aphasia in Post-stroke Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Jie Zhang; Ruili Wei; Zhongqin Chen; Benyan Luo
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

3.  Non-invasive brain stimulation as add-on therapy for subacute post-stroke aphasia: a randomized trial (NORTHSTAR).

Authors:  Anna Zumbansen; Sandra E Black; Joyce L Chen; Dylan J Edwards; Alexander Hartmann; Wolf-Dieter Heiss; Sylvain Lanthier; Paul Lesperance; George Mochizuki; Caroline Paquette; Elizabeth A Rochon; Ilona Rubi-Fessen; Jennie Valles; Heike Kneifel; Susan Wortman-Jutt; Alexander Thiel
Journal:  Eur Stroke J       Date:  2020-06-30

4.  Speech and language therapy for aphasia following subacute stroke.

Authors:  Engin Koyuncu; Pınar Çam; Nermin Altınok; Duygu Ekinci Çallı; Tuba Yarbay Duman; Neşe Özgirgin
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

5.  Psychosocial well-being in persons with aphasia participating in a nursing intervention after stroke.

Authors:  Berit Arnesveen Bronken; Marit Kirkevold; Randi Martinsen; Torgeir Bruun Wyller; Kari Kvigne
Journal:  Nurs Res Pract       Date:  2012-07-22

6.  Differential Effects of Speech and Language Therapy and rTMS in Chronic Versus Subacute Post-stroke Aphasia: Results of the NORTHSTAR-CA Trial.

Authors:  Anna Zumbansen; Heike Kneifel; Latifa Lazzouni; Anja Ophey; Sandra E Black; Joyce L Chen; Dylan Edwards; Thomas Funck; Alexander Erich Hartmann; Wolf-Dieter Heiss; Franziska Hildesheim; Sylvain Lanthier; Paul Lespérance; George Mochizuki; Caroline Paquette; Elizabet Rochon; Ilona Rubi-Fessen; Jennie Valles; Susan Wortman-Jutt; Alexander Thiel
Journal:  Neurorehabil Neural Repair       Date:  2022-03-25       Impact factor: 3.919

7.  Recent advances in the treatment of post-stroke aphasia.

Authors:  Anna Zumbansen; Alexander Thiel
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

8.  An Exploratory Investigation of E-Rest: Teletherapy for Chronically Aphasic Speakers.

Authors:  Marina B Ruiter; Toni C M Rietveld; Vera Hoskam; Marijn M A VAN Beers
Journal:  Int J Telerehabil       Date:  2016-07-01

9.  Evaluation of an Expert System for the Generation of Speech and Language Therapy Plans.

Authors:  Vladimir Robles-Bykbaev; Martín López-Nores; Jorge García-Duque; José J Pazos-Arias; Daysi Arévalo-Lucero
Journal:  JMIR Med Inform       Date:  2016-07-01

10.  Guideline adherence in speech and language therapy in stroke aftercare. A health insurance claims data analysis.

Authors:  Daniel Schindel; Lena Mandl; Ralph Schilling; Andreas Meisel; Liane Schenk
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.